WebDoctor Encyclopedia

Childhood

Retinoblastoma

Retinoblastoma is a cancer of the retina in young children, often first noticed as a white pupil reflex in photos; early treatment usually saves life and often sight.

Medically reviewed Last reviewed October 27, 2026

What is retinoblastoma?

Retinoblastoma (RB) is a rare cancer of the retina, the light-sensitive layer at the back of the eye. It develops almost exclusively in babies and young children.

It accounts for only about 3 % of childhood cancers, yet it is the most common eye cancer in children. It can affect one eye or both.

Untreated, retinoblastoma is fatal. With early diagnosis and modern treatment, more than 95 % of children in high-income countries survive, and many keep useful vision.

1. Epidemiology

Parameter Approximate Value Comments
Incidence 1 case per 15,000–20,000 live births worldwide Incidence is similar worldwide; most cases occur in Asia and Africa because of high birth rates
Age at diagnosis Median 12–18 months; 90 % diagnosed < 5 years Bilateral disease presents earlier (≈ 9 months) than unilateral (≈ 24 months)
Sex distribution Roughly equal male:female ratio No significant predilection
Laterality 60 % unilateral, 40 % bilateral Bilateral cases are almost always hereditary
Mortality < 5 % in high-resource settings with early detection; up to 70 % in low-resource settings Mortality correlates with delay > 6 months from symptom onset to treatment

2. Genetics and Molecular Pathogenesis

Retinoblastoma originates from a mutation in the RB1 tumour-suppressor gene located on chromosome 13q14.2. The “two-hit hypothesis” (Knudson, 1971) explains tumour initiation:

  1. First hit – germline (inherited) or somatic mutation in one RB1 allele.
  2. Second hit – loss of the remaining functional allele via mutation, deletion, mitotic recombination, or epigenetic silencing.

2.1 Heritable vs. Non-heritable Forms

Feature Heritable (Germline) RB Sporadic (Non-heritable) RB
RB1 mutation status Present in all constitutional cells (blood, saliva) Confined to tumour tissue
Laterality Predominantly bilateral or multifocal unilateral Almost always unilateral, unifocal
Risk of second primary cancers Elevated (osteosarcoma, soft-tissue sarcoma, melanoma, etc.) – especially after radiotherapy Baseline population risk
Family history Positive in only about a quarter of heritable cases; most are new germline mutations (autosomal dominant, about 90 % penetrance) Absent
Age of onset Earlier (median < 12 mo) Later (median ≈ 24 mo)
Screening implication Siblings and offspring need genetic testing & regular ocular exams No routine familial screening needed

2.2 Molecular Pathways

Loss of functional pRB protein leads to uncontrolled E2F-mediated transcription, driving cell-cycle progression from G₁ to S phase. Additional downstream effects include:

  • Genomic instability – increased susceptibility to chromosomal rearrangements.
  • Altered apoptosis – dysregulation of p53-dependent pathways.
  • Epigenetic changes – promoter hypermethylation of tumour-suppressor loci observed in aggressive tumours.

A small group of unilateral tumours in very young infants is driven by MYCN amplification with normal RB1 genes. These tumours tend to be large and grow quickly.

3. How Does It Look? (Clinical Appearance)

The hallmark of retinoblastoma is a white pupil reflex (leukocoria). Light reflects off the white tumour instead of the normal red retina, so the pupil can look white in flash photos or dim light.

Inside the eye, the tumour appears as a white or cream-coloured mass, often with chalky “cottage-cheese” flecks of calcium. Its appearance changes with size and with how far tumour cells have seeded into the eye.

3.1 Fundoscopic Findings

Group (International Classification of Retinoblastoma, ICRB) Typical appearance on eye examination
Group A Small grey-white, slightly translucent nodule within the retina (3 mm or less), no seeds.
Group B Larger white dome-shaped mass, sometimes near the macula or optic disc or with a little surrounding fluid under the retina; no seeds.
Group C White mass with small, localised seeds in the vitreous gel or under the retina close to the tumour.
Group D Large or multiple tumours with widespread seeds that look like white clumps or “snowballs” in the vitreous, often with retinal detachment.
Group E Massive tumour filling much of the eye; may cause glaucoma, bleeding, a cloudy cornea or cataract and loss of useful vision.

3.2 External Signs

  • Leukocoria – most common presenting sign; noticed in flash photographs or by caregivers observing a “cat’s eye” reflex.
  • Strabismus (misalignment of the eyes) – occurs when the tumour interferes with visual fixation, especially in unilateral disease.
  • Proptosis – forward bulging of the eye, typical of advanced Group E disease.
  • Iris colour changes – heterochromia or iris atrophy secondary to tumour invasion of the anterior segment.
  • Pain or redness – rare in early disease; may develop with secondary glaucoma, inflammation, or tumour necrosis.

Key point: A white pupil, especially together with a new squint, must always be checked urgently by an eye specialist. Other causes include congenital cataract, Coats disease and persistent fetal vasculature, but retinoblastoma has to be ruled out first.

4. Symptoms

While many infants are asymptomatic until a parent notices an abnormal eye sign, several symptoms may prompt medical attention.

4.1 Ocular Symptoms

  • White pupillary reflex (leukocoria) – noticed in photographs or low-light environments.
  • Decreased vision or visual inattention – the child may not fixate on objects, track moving toys, or respond to visual cues.
  • Eye misalignment (strabismus) – intermittent or constant esotropia (inward deviation) or exotropia (outward deviation).
  • Eye pain or irritation – reported in older children with advanced disease or secondary glaucoma.
  • Redness or swelling – conjunctival injection or lid edema due to inflammation or tumour necrosis.

4.2 Systemic / Non-ocular Symptoms (rare, usually late)

  • Failure to thrive – secondary to chronic illness or metabolic burden of malignancy.
  • Lethargy or irritability – nonspecific signs of discomfort.
  • Bone pain or pathological fracture – indicates metastatic spread (most commonly to bone marrow, bone, or CNS).
  • Neurological deficits – seizures, cranial nerve palsies, or altered mental status if intracranial metastasis occurs.

Note: The presence of systemic symptoms generally signifies advanced disease and warrants urgent oncologic work-up.

5. Diagnostic Work-up

A multidisciplinary approach (paediatric oncology, ophthalmology, genetics, radiology, pathology) is essential.

5.1 Clinical Examination

  1. Dilated fundus exam under general anaesthesia (or sedation) to characterise tumour size, location, seeding, and vitreous involvement.
  2. Ultrasound biomicroscopy (UBM) – assesses anterior segment involvement.
  3. Optical coherence tomography (OCT) – useful for detecting subretinal fluid and retinal thinning in cooperative older children.

5.2 Imaging

Modality Indication Typical Findings
B-scan ultrasonography First-line bedside tool; differentiates retinoblastoma from vitreous hemorrhage, Coats disease, etc. High-reflective, solid mass with calcifications (bright echoes); internal blood flow may be visible on Doppler.
Magnetic Resonance Imaging (MRI) – orbit & brain Staging for extra-ocular extension, optic nerve involvement, and CNS metastasis; avoids ionising radiation. Tumour appears slightly hyperintense on T1 and hypointense on T2 compared with the vitreous; calcifications appear as signal voids; enhancement post-gadolinium if viable tumour.
Computed Tomography (CT) – head/orbit Used only when MRI is unavailable; avoided especially in heritable cases because radiation raises the risk of second cancers. Calcifications appear hyperdense; tumour mass shows moderate contrast enhancement.
Bone marrow aspirate & biopsy Staging for metastatic disease (especially in high-risk groups). Presence of tumour cells indicates stage IV disease.
Lumbar puncture Evaluate for meningeal/CNS seeding (rare but lethal). CSF cytology positive for tumour cells.

Radiation safety: CT is reserved for specific situations because the developing brain and ocular tissues are highly radiosensitive; MRI is preferred whenever feasible.

5.3 Genetic Testing

  • Blood (or saliva) DNA analysis for RB1 germline mutation – determines heritability, guides family screening, and informs risk of second malignancies.
  • Tumour genotyping (if tissue available) – identifies somatic second hit, copy-number variations, and potential therapeutic targets (e.g., MYCN amplification).
  • Multiplex ligation-dependent probe amplification (MLPA) and next-generation sequencing (NGS) are standard platforms.

5.4 Pathology (when enucleation performed)

Histopathology confirms diagnosis and provides prognostic markers:

  • Flexner-Wintersteiner rosettes – hallmark of retinoblastoma.
  • Homer-Wright rosettes – suggest poorer differentiation.
  • Lymphovascular invasion, optic nerve resection margin involvement, scleral or choroidal invasion – upstage disease and influence adjuvant therapy.
  • Immunohistochemistry: loss of RB protein staining and the Ki-67 proliferation index can support the diagnosis.

6. Staging Systems

Two main systems are used clinically:

6.1 International Classification of Retinoblastoma (ICRB) – Intra-ocular

Group Definition Treatment Implication
A Tumor ≤ 3 mm, confined to retina, no vitreous or subretinal seeding. Local therapies (laser or cryotherapy).
B Tumour larger than 3 mm, or close to the fovea or optic disc, or with a small amount of subretinal fluid; no seeding. Systemic or intra-arterial chemotherapy plus local therapy.
C Focal subretinal or vitreous seeding within 3 mm of the tumour. Systemic or intra-arterial chemotherapy plus local therapy.
D Diffuse vitreous or subretinal seeding more than 3 mm from the tumour; disease still confined to the globe. Systemic or intra-arterial chemotherapy, often with intravitreal injections; enucleation if unresponsive.
E Tumor massive, irreversible globe damage, presence of anterior segment invasion, neovascular glaucoma, tumor prolapse, or lack of useful vision; enucleation required. Primary enucleation; adjuvant therapy based on pathologic risk factors.

6.2 International Retinoblastoma Staging System (IRSS) – for spread beyond the eye

The IRSS describes whether the cancer has been completely removed and whether it has spread outside the eye. The AJCC TNM system (8th edition) is also used, mainly in research and registries.

Stage Criteria Prognosis
0 Disease inside the eye, treated without removing the eye. Excellent with early treatment.
I Eye removed, and pathology shows the tumour was completely removed. Excellent.
II Eye removed, but microscopic tumour remains, for example at the cut end of the optic nerve or in the outer eye wall. Good with additional chemotherapy and orbital radiotherapy.
III Regional spread: visible tumour in the eye socket (orbit) or in lymph nodes in front of the ear or in the neck. Guarded; needs intensive chemotherapy, surgery and radiotherapy.
IV Distant metastasis: IVa to bone, bone marrow or other organs through the blood; IVb spread to the brain or spinal fluid. Poor, especially with brain involvement; high-dose chemotherapy with stem-cell rescue.

7. Treatment Modalities

Treatment is individualized based on laterality, group, presence of hereditary mutation, and patient age. The overarching goals are globe salvage (when possible), preservation of vision, minimization of treatment-related morbidity, and prevention of metastasis.

7.1 Local Therapies (for small, confined tumors)

Modality Mechanism Indications Advantages Limitations
Laser photocoagulation (argon or diode) Thermal coagulation of tumor vasculature Group A/B tumors ≤ 3 mm, peripheral Non-invasive, outpatient, repeatable Ineffective for tumors near macula or optic disc; requires clear media.
Cryotherapy Freeze-thaw cycles causing cellular necrosis Anterior or peripheral tumors Effective for tumors opaque to laser; can be combined with chemo Risk of cataract, retinal detachment, lid edema.
Thermotherapy (transpupillary infrared) Mild heat (42-45 °C) enhances chemo uptake Adjunct to systemic chemo (chemothermotherapy) Synergistic effect reduces systemic dose Requires specialized equipment; limited depth penetration.
Plaque brachytherapy (iodine-125 or ruthenium-106) Radioactive plaque sewn temporarily onto the eye wall over the tumour Selected solitary tumours, often after chemotherapy, where globe salvage is desired High local control; avoids external beam radiation Requires surgical plaque placement; risk of radiation retinopathy/optic neuropathy if dose too high.

7.2 Systemic Chemotherapy

  • First-line regimens (based on Children’s Oncology Group and European studies):
  • Vincristine + Etoposide + Carboplatin (VEC) – 3- to 4-week cycles, usually 6 cycles.
  • Adjuvant chemotherapy after enucleation – VEC or regimens adding cyclophosphamide and doxorubicin when pathology shows high-risk features.
  • Topotecan + Cyclophosphamide – for relapsed/refractory disease.

  • Administration – intravenous via central line; dose adjustments for renal/hepatic function.

  • Goals – shrink tumors to enable local therapy, treat microscopic disease, prevent metastasis.

  • Side effects – myelosuppression (neutropenia, anemia, thrombocytopenia), alopecia, nausea/vomiting, ototoxicity (carboplatin), cardiotoxicity (doxorubicin), secondary malignancy risk (especially with etoposide).

7.3 Intra-arterial Chemotherapy

  • Technique – a fine catheter is passed from the groin artery to the ophthalmic artery, and chemotherapy (usually melphalan, sometimes with topotecan or carboplatin) is delivered directly to the eye.
  • Indications – unilateral Group B–D disease and some bilateral cases; repeated every 3–4 weeks for about 3 cycles.
  • Advantages – high drug levels in the eye with few whole-body side effects; has greatly improved eye salvage in advanced intra-ocular disease.
  • Risks – vascular problems in the eye, eyelid swelling and, rarely, stroke-like events; performed only in specialised centres.

7.4 Intravitreal Chemotherapy

  • Melphalan (most common) – delivered via pars plana injection under anaesthesia.
  • Topotecan – alternative for melphalan-resistant cases.
  • Indications – persistent vitreous seeding after systemic chemo, or as primary therapy for selected Group D eyes.
  • Safety – risk of retinal toxicity, vitreous hemorrhage, retinal detachment, and (rare) extra-ocular spread if technique flawed; special injection techniques and strict dosing are used to prevent this.

7.5 External Beam Radiation Therapy (EBRT)

  • Once a main eye-saving treatment, especially in bilateral disease; now reserved for high-risk retinoblastoma (e.g., massive orbital extension, optic nerve involvement with positive margins) due to late effects:
  • Radiation retinopathy (microvascular abnormalities, macular edema).
  • Cataract and dry eye.
  • Growth retardation of facial bones.
  • Increased risk of second malignancies (especially osteosarcoma, soft-tissue sarcoma) in hereditary patients.

  • Modern techniques – intensity-modulated radiotherapy (IMRT) or proton therapy aim to spare surrounding tissues, yet long-term data remain limited.

7.6 High-Dose Chemotherapy with Autologous Stem-Cell Rescue (HDCSR)

  • Indicated for metastatic (stage IV) or high-risk recurrent disease.
  • Regimens often include carboplatin, thiotepa and etoposide followed by stem-cell reinfusion.
  • Provides intensive tumour control while rescuing marrow function.

7.7 Experimental Therapies

Research is testing oncolytic viruses injected into the eye (such as VCN‑01), drugs that target cell-cycle and survival pathways, and new immunotherapies. These are available only within clinical trials at specialised centres.

Take‑away: Standard care remains chemotherapy (systemic, intra‑arterial or intravitreal) combined with local therapies, with enucleation for eyes that cannot be saved.

8. Prognosis

Factor Impact on Survival
Early detection (ICRB A/B) > 95 % 5-year survival with high likelihood of globe and vision preservation.
Advanced intra-ocular disease (Group D/E) Many Group D eyes can now be saved, especially with intra-arterial chemotherapy; Group E eyes are usually removed. Survival stays above 95 % if the cancer has not spread outside the eye.
Orbital involvement (Stage III) Survival around 60-70 % in specialised centres with intensive multimodal therapy.
Metastatic disease (Stage IV) Roughly 60-70 % survival with high-dose chemotherapy and stem-cell rescue when the brain is not involved; very poor with CNS spread.
Heritable RB1 mutation Eye-cancer survival is similar with timely treatment, but the lifetime risk of second cancers (mainly sarcomas and melanoma) is high, around one-third by age 50 and higher after radiotherapy. A rare related tumour in the pineal gland (trilateral retinoblastoma) can also occur.
Treatment-related complications Vision loss, endocrine disturbances (growth hormone deficiency after cranial irradiation), hearing loss, cardiotoxicity, secondary cancers – affect quality of life more than mortality in long-term survivors.

Overall, mortality from retinoblastoma in high-income countries is < 5 %, largely attributable to delays in diagnosis or lack of access to specialized centers.

9. Follow-up and Surveillance

9.1 Ophthalmic Surveillance

Time after treatment Examination Purpose
Every 3 months (first 2 years) Dilated fundus exam under anaesthesia (if child < 5 y) or cooperative exam (older) Detect recurrence, new tumors, or treatment-related changes (e.g., radiation retinopathy).
Every 6 months (years 2-5) Same as above Late recurrence risk declines after 2 years but persists.
Annually thereafter Full ophthalmic exam (including OCT, visual fields if age appropriate) Monitor for long-term effects: cataract, glaucoma, retinal detachment, optic neuropathy.
Lifelong Annual eye exam (including intra-ocular pressure) Surveillance for second primary ocular malignancies (rare) and visual rehabilitation needs.

9.2 Oncologic Surveillance

  • History & physical every 3–6 months for the first 2 years, then every 6 months up to 5 years, focusing on signs of metastasis (bone pain, lymphadenopathy, neurological symptoms).
  • Laboratory tests – CBC with differential (to monitor marrow recovery), LDH, liver/renal function as clinically indicated.
  • Imaging – MRI of the brain and orbits is often repeated in children with heritable disease (to look for trilateral retinoblastoma) and after high-risk pathology.
  • Audiology – baseline and periodic (every 6-12 months) if platinum-based chemo used.
  • Endocrine assessment – yearly growth velocity, thyroid function, pubertal staging if cranial irradiation administered.

9.3 Genetic Counselling & Family Screening

  • The child – every child with retinoblastoma should be offered RB1 germline testing, including those with one-sided disease.
  • Parents and siblings – tested for the family mutation once it is known; siblings who test negative do not need repeated eye examinations.
  • Offspring of an RB1 carrier – 50 % risk; prenatal testing (CVS or amniocentesis) or pre-implantation genetic diagnosis (PGD) available.
  • Ocular screening – children at risk are examined soon after birth and then frequently (roughly every 1–3 months at first, often under anaesthesia) until about age 3, then less often until school age.

10. Psychosocial and Supportive Care

A diagnosis of retinoblastoma impacts the entire family. Comprehensive care includes:

  • Parent education – clear explanation of disease, treatment plan, and expected outcomes.
  • Developmental support – early intervention services (speech, occupational therapy) for children with visual impairment.
  • School re-integration – liaison with educators for visual accommodations (large print, assistive technology).
  • Psychological counseling – for anxiety, post-traumatic stress, and adjustment disorders in patients and caregivers.
  • Financial assistance – navigation of insurance, charitable foundations, and travel support for treatment at specialty centres.
  • Survivorship clinics – long-term follow-up addressing secondary cancer screening, fertility concerns (if gonadotoxic agents used), and quality-of-life assessment.

11. Resources

  1. Dimaras, H. et al. (2015) ‘Retinoblastoma’, Nature Reviews Disease Primers, 1, 15021.
  2. Global Retinoblastoma Study Group (2020) ‘Global retinoblastoma presentation and analysis by national income level’, JAMA Oncology, 6(5), pp. 685-695.
  3. Chantada, G. et al. (2006) ‘A proposal for an international retinoblastoma staging system’, Pediatric Blood & Cancer, 47(6), pp. 801-805.
  4. Kleinerman, R.A. et al. (2005) ‘Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up’, Journal of Clinical Oncology, 23(10), pp. 2272-2279.
  5. National Cancer Institute (2026) Retinoblastoma Treatment (PDQ®) – Health Professional Version. Available at: https://www.cancer.gov/types/retinoblastoma/hp/retinoblastoma-treatment-pdq (Accessed: October 2026).
  6. American Cancer Society (2026) Retinoblastoma. Available at: https://www.cancer.org/cancer/types/retinoblastoma.html (Accessed: October 2026).
  7. American Academy of Ophthalmology (2026) Retinoblastoma, EyeWiki. Available at: https://eyewiki.org/Retinoblastoma (Accessed: October 2026).

12. Conclusion

Thanks to genetics, early detection and specialised treatment, retinoblastoma has gone from a lethal childhood cancer to a highly treatable one. The key points are:

  1. Leukocoria and strabismus are the red-flag signs that should prompt immediate ophthalmic evaluation.
  2. Genetic testing clarifies heritability, guides family screening, and influences long-term cancer surveillance.
  3. Staging (ICRB for disease inside the eye; IRSS or TNM for spread beyond it) directs therapy intensity and prognostic counseling.
  4. Modern management favors globe-sparing strategies—systemic or intra-arterial chemotherapy combined with laser, cryotherapy, thermotherapy or intravitreal melphalan—reserving enucleation for advanced, unresponsive disease.
  5. Long-term follow-up is essential to monitor for recurrence, treatment-related sequelae, and the heightened risk of second malignancies in hereditary cases.
  6. Psychosocial support, genetic counselling, and access to specialised centres dramatically improve quality of life and survival outcomes.

Prepared by the editorial team, October 2026.